Number of participants who experienced a flare ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in health‐related quality of life ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in disease severity as assessed by the participants (number of participants who considered their skin to have improved) · people with eczema
All moisturisers may leads to higher change from baseline in disease severity as assessed by the… compared with vehicle, placebo or no moisturiser (low certainty).
1 finding from 1 review
Participant satisfaction · people with eczema
All moisturisers showed no clear difference in participant satisfaction compared with vehicle, placebo or no moisturiser (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · people with eczema
All moisturisers showed no clear difference in number of participants reporting an adverse event compared with vehicle, placebo or no moisturiser (moderate certainty).
1 finding from 1 review
Change from baseline in disease severity as assessed by the investigators · people with eczema
1 finding from 1 review
Number of participants who experienced a flare · people with eczema
All moisturisers probably leads to lower number of participants who experienced a flare compared with vehicle, placebo or no moisturiser (moderate certainty).
1 finding from 1 review
Total amount of topical corticosteroids used · people with eczema
1 finding from 1 review
Change from baseline in health‐related quality of life · people with eczema
1 finding from 1 review
Proportion of participants with self‐rated clinically significant hair regrowth · women with FPHL
Minoxidil probably leads to higher the proportion of participants with self‐rated clinically… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants with self‐rated clinically significant hair regrowth · women with FPHL
Finasteride showed no clear difference in the proportion of participants with self‐rated clinically… compared with placebo (low certainty).
1 finding from 1 review
Change in quality of life ‐ not measured · women with FPHL
1 finding from 1 review
Adverse events · women with FPHL
Finasteride showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Change in quality of life · women with FPHL
1 finding from 1 review
Proportion of participants with investigator‐rated clinically significant hair regrowth · women with FPHL
Finasteride showed no clear difference in proportion of participants with investigator‐rated clinically… compared with placebo (low certainty).
1 finding from 1 review
Change from baseline to study conclusion in total hair count · women with FPHL
1 finding from 1 review
Degree of hair shedding from baseline to the end of the study · women with FPHL
1 finding from 1 review
Cosmetic appearance of the hair or participant satisfaction · women with FPHL
Finasteride showed no clear difference in cosmetic appearance of the hair or participant satisfaction compared with placebo (low certainty).
1 finding from 1 review
Change in quality (or pattern) of hair regrowth (e.g. thickness) ‐ not measured · women with FPHL
1 finding from 1 review